Patent ID: 8329696

Claim:
A crystalline form of Sitagliptin sulfate, designated Form S2, characterized by data selected from: a powder X-ray diffraction pattern with peaks at 9.3°, 9.7°, 15.2°, 15.6° and 25.4°±0.2° 2θ; a powder X-ray diffraction pattern as shown in FIG. 1 b ; a solid-state 13 C NMR spectrum with signals at 119.2, 150.3 and 170.6±0.2 ppm; a solid-state 13 C NMR spectrum having chemical shifts differences between the signal exhibiting the lowest chemical shift and another in the chemical shift range of 100 to 180 ppm of 13.7, 44.8 and 65.1±0.1 ppm; a 13 C NMR spectrum as depicted in FIG. 1 m and FIG. 1 n ; and combinations thereof.